Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer’s Disease – Markets Insider

Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer’s DiseaseMarkets InsiderIONIS-MAPTRx is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain. Tau misfolding leads to the accumulation of neurofibrillary tangles inside brain cells. These …Biogen Pays Ionis $10M as Phase I/IIa Trial Launched for Alzheimer’s Candidate IONIS-MAPTRxGenetic Engineering & Biotechnology NewsIonis launches an early-stage tau drug study for Alzheimer’s, picking up $10M from BiogenEndpoints NewsIonis earns $10M milestone on launch of Phase 1/2a study of …Seeking AlphaStreetInsider.comall 6 news articles »

Read More

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Closed Well Above Its 50 Day Average – HugoPress

HuronReportBio-Path Holdings, Inc. (NASDAQ:BPTH) Closed Well Above Its 50 Day AverageHugoPressThe Business’s drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when …Bio-Path Holdings Inc. (BPTH) Plunges 6.46% on October 12Equities.comBio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Traded Significantly …Highlight PressWFG Advisors LP Has $170000 Position in Bio-Path Holdings Inc (BPTH)BangaloreWeeklyall 70 news articles »

Read More

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Traded Significantly Above … – First News 24

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Traded Significantly Above …First News 24Company shares are trading at $0.39 much higher than the 50 day moving average of $0.33 and which is significantly below the 200 day moving average of …Bio-Path Holdings Inc. (BPTH) Soars 6.52% on October 09Equities.comBio-Path Holdings (BPTH) Broker Price Targets For The Coming …Fiscal Standardall 10 news articles »

Read More

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Closed Much Higher Than Its 50 Day Moving Average – HugoPress

BZ WeeklyBio-Path Holdings, Inc. (NASDAQ:BPTH) Closed Much Higher Than Its 50 Day Moving AverageHugoPressThe Business’s drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when …Will Bio Path Holdings DE (NASDAQ:BPTH) Run Out of Steam Soon …BZ WeeklyTower Research Capital Trc Has Upped Its Trinity Inds (TRN) Stake; Bio-path Holdings (BPTH)’s Sentiment Is 0.67Wolcott Dailyall 6 news articles »

Read More

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Significantly Lower Trading Volume – First News 24

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Significantly Lower Trading VolumeFirst News 24The Business’s drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when …Bio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Traded Significantly …Highlight PressBrokers Release Average Price Target Of 4.67 On Bio-Path Holdings (BPTH)UK Market NewsLegal & General Group Plc Increases Holdings in Bio-Path Holdings …Week Heraldall 9 news articles »

Read More

Global Cancer Drug Delivery Technologies, Markets and Companies Research Report 2017 – Projections to 2026 – Markets Insider

Global Cancer Drug Delivery Technologies, Markets and Companies Research Report 2017 – Projections to 2026Markets InsiderThese include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of …and more »

Read More

Global Cancer Drug Delivery Technologies, Markets and Companies Research Report 2017 – Projections to 2026 – GlobeNewswire (press release)

Global Cancer Drug Delivery Technologies, Markets and Companies Research Report 2017 – Projections to 2026GlobeNewswire (press release)These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of …and more »

Read More

Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function … – Markets Insider

Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function …Markets InsiderBiogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals (NASDAQ: IONS), a leader in antisense therapeutics. Biogen and Ionis conducted an innovative clinical development program that moved …and more »

Read More

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Traded 14.4 … – First News 24

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Traded 14.4 …First News 24The stock last traded at $0.37 which is quite a bit above $0.33, the 50 day moving average and which is significantly lower than the 200 day moving average of …Bio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Traded Significantly …Highlight PressLegal & General Group Plc Increases Holdings in Bio-Path Holdings …Week HeraldBrokers Release Average Price Target Of 4.67 On Bio-Path …UK Market Newsall 6 news articles »

Read More

Reductive nanocomplex encapsulation of cRGD-siRNA conjugates for enhanced targeting to cancer cells – Dove Medical Press

Reductive nanocomplex encapsulation of cRGD-siRNA conjugates for enhanced targeting to cancer cellsDove Medical PressCompared with the gene silencing of different conjugates, single or bis-cRGD-conjugated siRNA showed little differences except 22 (5/5) which cRGD was conjugated at 5′-terminus of antisense strand and sense strand. However bis-cRGD conjugate 21 …

Read More

FDA Clears Antisense Therapeutics to Proceed with Phase 2b Trial of ATL1102 in RRMS and SPMS Patients – Multiple Sclerosis News Today

Multiple Sclerosis News TodayFDA Clears Antisense Therapeutics to Proceed with Phase 2b Trial of ATL1102 in RRMS and SPMS PatientsMultiple Sclerosis News TodayAntisense Therapeutics announced that it is proceeding with a Phase 2b clinical trial of ATL1102, its lead candidate to treat multiple sclerosis, after the U.S. Food and Drug Administration (FDA) lifted a clinical hold it had placed on the company’s …

Read More

Akcea Therapeutics Canada Appoints Nelly Komari, B. Pharm., MSc. as Medical Director – Markets Insider

Akcea Therapeutics Canada Appoints Nelly Komari, B. Pharm., MSc. as Medical DirectorMarkets InsiderVolanesorsen, a product of Ionis’ proprietary antisense technology, is in development for two rare metabolic disorders: familial chylomicronemia syndrome (FCS) and familial partial lipdystrophy (FPL). Volanesorsen is designed to reduce the production …Akcea Therapeutics (AKCA) Reaches $29.31 After 8.00% Up Move; Noodles & Company Class A (NDLS) Shorts …Key GazetteAkcea Therapeutics, Inc. (AKCA) Sees Large Increase in Short InterestMarea Informative (blog)all 4 news articles »

Read More

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Unusual Trading Volume in Its Shares – First News 24

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Unusual Trading Volume in Its SharesFirst News 24The Business’s drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when …Bio-Path Holdings Inc. (BPTH) Soars 5.41% on October 03 | Equities …Equities.comall 10 news articles »

Read More

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Unusual Trading Volume in Its Shares – First News 24

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Unusual Trading Volume in Its SharesFirst News 24The Business’s drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when …Researchers At Zacks Anticipate Bio-Path Holdings, Declare -$0.02 …Highland MirrorBio-Path Holdings (BPTH) Receiving Somewhat Favorable News …Week HeraldZacks: Analysts Expect Bio-Path Holdings, Inc. (BPTH) to Announce …The Ledger GazetteUK Market Newsall 7 news articles »

Read More

#IARC2017 – Synthetic Molecules Seen to Restore Frataxin Protein Levels in Cells from FA Patients – Friedreich’s Ataxia News

#IARC2017 – Synthetic Molecules Seen to Restore Frataxin Protein Levels in Cells from FA PatientsFriedreich’s Ataxia NewsThe presentation, by David Corey at the University of Texas Southwestern, was titled “Activation of Frataxin expression by duplex RNAs and antisense oligonucleotides,” and was part of Session 4: Therapeutics and Clinical Trials on Friday at IARC.and more »

Read More